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Explant analysis of AneuRx stent grafts:
Relationship between structural findings and
clinical outcome
Christopher K. Zarins, MD,a Frank R. Arko, MD,a Tami Crabtree, MS,a Daniel A. Bloch, PhD,a
Kenneth Ouriel, MD,b Robert C. Allen, MD,c and Rodney A. White, MD,d Stanford, Calif; Cleveland,
Ohio; Naples, Fla; and Los Angeles, Calif
Objective: We reviewed the structural findings of explanted AneuRx stent grafts used to treat abdominal aortic aneurysms,
and relate the findings to clinical outcome measures.
Methods: We reviewed data for all bifurcated AneuRx stent grafts explanted at surgery or autopsy and returned to the
manufacturer from the US clinical trial and worldwide experience of more than 33,000 implants from 1996 to 2003.
Devices implanted for more than 1 month with structural analysis are included in this article. Explant results were
analyzed in relation to cause of explantation and pre-explant evidence of endoleak, enlargement, or device migration.
Results: One hundred twenty explanted stent grafts, including 37 from the US clinical trial, were analyzed. Mean implant
duration was 22  13 months (range, 1-61 months). Structural abnormalities included stent fatigue fractures, fabric
abrasion holes, and suture breaks. The mean number of nitinol stent strut fractures per explanted device was 3 4, which
represents less than 0.2% of the total number of stent struts in each device. The mean number of fabric holes per explanted
device was 2  3, with a median hole size of 0.5 mm2. Suture breaks were seen in most explanted devices, but composed
less than 1.5% of the total number of sutures per device. “For cause” explants (n  104) had a 10-month longer implant
duration (P .007) compared with “incidental” explants (n 16). “For cause” explants had more fractures (3 5; P
.005) and fabric holes (2  3; P  .008) per device compared with “incidental” explants, but these differences were not
significant (P .3) when adjusted for duration of device implantation. Among clinical trial explants the number of fabric
holes in grafts in patients with endoleak (2  3 per device) was no different from those without endoleak (3  4 per
device; P  NS). The number of fatigue fractures or fabric holes was no different in grafts in clinical trial patients with
pre-explant aneurysm enlargement compared with those without enlargement. Pre-explant stent-graft migration was
associated with a greater number of stent strut fractures (5  7 per device; P  .04) and fabric holes (3  3 per
bifurcation; P  .03) compared with explants without migration. Serial imaging studies revealed inadequate proximal,
distal, or junctional device fixation as the probable cause of rupture or need for conversion to open surgery in 86% of “for
cause” explants. Structural device abnormalities were usually remote from fixation sites, and no causal relationship
between device findings and clinical outcome could be established.
Conclusions: Nitinol stent fatigue fractures, fabric holes, and suture breaks found in explanted AneuRx stent grafts do not
appear to be related to clinical outcome measures. Longer term studies are needed to confirm these observations. (J Vasc
Surg 2004;40:1-11.)Endovascular repair has gained wide acceptance in the
treatment of abdominal aortic aneurysm, with favorable
From the Division of Vascular Surgery and Health Research and Policy,
Stanford University Medical Center,a Stanford, Calif, the Department of
Vascular Surgery, The Cleveland Clinic Foundation,b Cleveland, The
Department of Vascular Surgery, The Cleveland Clinic,c Naples, and the
Division of Vascular Surgery, Harbor-UCLA Medical Center,d Los An-
geles.
Competition of interest: The authors are paid consultants for Medtronic and
may have equity interest in the company.
Presented at the Eighteenth Annual Meeting of the Western Vascular
Society, Kohala Coast, HI, Sep 20-23, 2003.
Reprint requests: Christopher K. Zarins, MD, Stanford University Medical
Center, Division of Vascular Surgery, 300 Pasteur Dr, H3642, Stanford,
CA 94305-5642 (e-mail: zarins@stanford.edu).
0741-5214/$30.00
Copyright © 2004 by The Society for Vascular Surgery.
doi:10.1016/j.jvs.2004.03.008results with a variety of devices.1-6 However, adverse
events, including aneurysm rupture, migration, endoleak,
and aneurysm enlargement, are cause for concern.7-11 Ad-
verse clinical events may result from device structural fail-
ure, including hook fractures, stent corrosion, stent frac-
tures, and fabric tears.12-17 However, the relationship
between structural characteristics of implanted endovascu-
lar devices, clinical performance, and long-term outcome of
endovascular aneurysm repair is poorly understood.18 Most
reports of device mechanical failure have been largely based
on radiographic findings,19 and few explanted devices have
been subjected to detailed morphologic and structural
analysis.20 The purpose of this investigation was to evaluate
the structural characteristics of explanted AneuRx stent
grafts and to relate the findings to clinical outcome mea-
sures.1
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AneuRx stent-graft structure. The AneuRx stent
graft is composed of an exoskeleton of nitinol stent rings
sutured to a polyester fabric graft. The bifurcation module
contains seven aortic rings and 14 to 17 iliac rings, depend-
ing on the length of the stent graft. There are 728 to 1020
(mean, 907  82) nitinol diamond strut elements in each
bifurcation module. The initial bifurcation design con-
tained a single 5-cm long bifurcated stent segment, which
resulted in a stiff bifurcation. This was used in the early
clinical experience and in the first 174 patients in the clinical
trial. The current segmented bifurcation design, used in
1019 patients in the clinical trial, includes 1-cm long stent
rings throughout the stent graft, which results in a flexible
bifurcation (Fig 1). The woven polyester fabric material
used in current AneuRx devices was introduced in Decem-
ber 1997 during the clinical trial. This reduced porosity
Fig 1. Nitinol exoskeleton is composed of individual 1-cm long
stent rings (top) joined end-to-end and attached to the graft fabric
with sutures. Each stent diamond has four struts. The early proto-
type “stiff” bifurcation module (bottom left) had a single 5-cm long
bifurcation stent. The flexible segmented design (bottom right) was
used in most clinical trial patients, and is the design used in the
commercially marketed stent graft.material (RPM) fabric was used in 936 patients in the
clinical trial; in the initial 257 clinical trial patients a less
densely woven polyester fabric (preRPM fabric) was used
(Fig 2). Stent rings are joined to each other and to the
fabric with 5-0 polyester sutures. There are 1619 to 2079
suture attachments in each bifurcation module.
Method. All bifurcated AneuRx stent-graft devices
implanted from June 1996 to July 2003, and subsequently
explanted and returned to the manufacturer (Medtronic
Vascular) were reviewed (N 161). Devices returned after
unsuccessful implantation or those in place for less than 30
days were excluded from this analysis (n  28), as were 13
explanted devices with no structural analysis because of
histologic sectioning. One hundred twenty explanted de-
vices from the worldwide experience, including 37 ex-
planted in the US clinical trial, are included in this report.
Explant analysis included gross inspection and photog-
raphy of the “as received” specimen, x-ray imaging, tissue
digestion and cleaning of the stent graft, magnified optical
imaging, and ultrastructural analysis of the stent graft.
Scanning electron microscopy of each stent fracture surface
was used to differentiate acute overload fractures (induced
by mechanical trauma during the explant procedure) from
fatigue fractures (present in vivo before explantation).
Overload fractures were characterized by micro-ovoid co-
alescence surface anatomy, whereas fatigue fractures
showed radial lines that originated at the fracture origin and
fanned out parallel to the direction of crack growth21 (Fig
2). Graft defects included fabric weave separation, fabric
abrasion holes, and explantation-induced cuts. The con-
tour of each fabric defect was traced, and cross-sectional
area was calculated with Scion Image Software, version
4.0.2. Fabric holes were defined as defects larger than 0.2
mm2 in cross-section, the manufacturing specification for
the graft fabric and the approximate cross-sectional area of
a 25-gauge needle. Suture abnormalities included fraying
and broken sutures.
The primary and secondary reasons for surgical conver-
sion and stent-graft explantation were determined from the
explanting surgeon’s operative report and clinical sum-
mary. The cause of death, and the status of the aneurysm
and stent graft were determined from the autopsy report.
All explants retrieved at surgical conversion, as well as those
retrieved at autopsy where the cause of death was aneurysm
rupture or stent-graft complication, were grouped as “for
cause” explants. Explants retrieved at autopsy where the
cause of death was unrelated to the aneurysm or stent graft
were considered “incidental” explants. Clinical records,
and preoperative and post-implantation imaging studies
were reviewed by two experienced surgeons, independent
of explant findings, to determine the reason for clinical
events leading to “for cause” explantation. For the 37
clinical trial explants, pre-explant imaging evidence of en-
doleak, aneurysm enlargement, or stent-graft migration, as
determined by the core laboratory (phase II patients) or
clinical center (phase III patients), were related to quanti-
tative explant analysis findings.
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SD for continuous data, and as percentage for categorical
data. Differences among groups were determined with the
Wilcoxon rank sum test for continuous data, and the 2 or
Fisher exact test for binary comparisons. Analysis of covari-
ance was performed to adjust for factors that were unbal-
anced between the groups and could potentially affect the
outcomes. Differences at P  .05 were considered statisti-
cally significant.
RESULTS
Explant patient population. The explant patient co-
hort (N  120) was similar to the population of patients
treated in the US clinical trial.1 Mean age in the explant
patient group at the time of device implantation (72  7
years) was not different from age in the clinical trial patient
group (73  8 years). There was no difference in gender
distribution between the explant (88% men, 12% women)
and clinical trial groups (89% men, 11% women). Mean
duration of device implantation before explantation was 22
 13 months (range, 1-61 months). The distribution of
stiff versus flexible bifurcation module stent design in the
worldwide explant group (5% vs 95%) was significantly
different from the distribution among clinical trial patients
(14% vs 86%; P .004). The distribution of preRPM versus
RPM fabric in the worldwide explant group was 11% versus
89%, significantly different from the distribution in clinical
trial patients (21% vs 79%; P  .008).
Fig 2. A, Explanted device demonstrates a broken sutur
in stent ring 4. B, Scanning electron microscopy image co
fault lines visible on the fracture surface. C, Reduced poro
trial and in the commercially marketed stent graft. D, Pr
weave.Reasons for explantation. The primary and second-
ary reasons for device explantation, as determined by the
explanting physician, are shown in Table I. Aneurysm
enlargement with or without endoleak was the most com-
mon reason for surgical conversion, followed by aneurysm
rupture and stent-graft migration. Three autopsy explants
(two in the clinical trial group) were from patients who died
of aneurysm rupture, and are included among the “for
cause” rupture explants. There were 104 “for cause” ex-
plants and 16 “incidental” autopsy explants.
Nitinol stent fatigue fractures. One or more mitinol
stent fatigue fractures were observed in 66% of explanted
devices, and no fractures in 34% of devices. The mean
number of strut fractures per explanted device was 3  4
(range, 0-29). Stent strut fractures represented less than
0.2% of the total number of stent struts in each device. The
total number of fatigue fractures per explanted device is
shown in Fig 3. Only six explants (5%) had 10 or more strut
fractures. The maximum number of strut fatigue fractures
in a bifurcation module was 13. The maximum number of
fractures in any module was 29, and were found in an aortic
extender cuff that was severely angulated and distorted.
The distribution of stent fractures among modular
device components is shown in Table II. Most fatigue
fractures were found in the bifurcation module, with 2 3
fractures per bifurcation. Bifurcation fractures were associ-
ated with severe neck angulation, and were usually located
in aortic stent rings 3 (70% of fractures) and 4 (12% of
ween aortic stent rings 3 and 4, and a stent strut fracture
s that this stent strut fracture is a fatigue fracture, by the
aterial (RPM) fabric used in most patients in the clinical
fabric used in the initial devices had a less dense fabrice bet
nfirm
sity m
eRPM
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tions to a bi-oval configuration. Iliac limb fractures were
less common, and were localized in areas of severe iliac
angulation. Fatigue fractures were rarely seen in the seal
zones of the device to the aortic neck or iliac arteries or in
the modular iliac junction.
Fabric holes and weave separation. Fabric weave
separation was observed in explants with the early preRPM
fabric, and was most prominent in areas of suture pull and
fabric stretch in severe angulations and bends. Weave sep-
aration resulted in spaces between fabric fibers of less than
0.2 mm2. Fabric abrasion and fabric holes were related to
wear of the fabric against the apex of metallic stent dia-
monds in areas of severe angulation and suture breaks.
Fabric holes were rarely seen in relation to stent strut
fractures.
One or more fabric holes larger than 0.2 mm2 were
observed in 45% of explanted devices, and no fabric holes
were found in 55% of devices. The mean number of holes
per explanted device was 2  3 (range, 0-17). Mean fabric
Table I. Reason for graft explanation
Worldwide
(N  120)
Clinical trial
(N  37)
104 31
“For cause” explanation
Rupture* 17 7
Symptomatic AAA 3 0
Component separation or
migration
3 0
Aneurysm enlargement 3 3
Endoleak or inadequate
seal
4 1
Unknown 4 3
Symptomatic AAA
(nonruptured)
4 0
Migration 1
Aneurysm enlargement 1
Endoleak 1
Infection 1
Component separation 4 5
Migration 14 2
Aneurysm enlargement 39 15
Endoleak 31 12
Type I 6 4
Type II 14 2
Type III 6 3
Unknown source 5 3
No endoleak 8 3
Endoleak without
enlargement
11 0
Type I 9
Type II 1
Type III 1
Aortoenteric fistula 4 2
Infection 4 0
Limb occlusion 7 0
“Incidental” autopsy
explantation
16 6
AAA, Abdominal aortic aneurysm.
*Three grafts in worldwide group and two in clinical trial group were
explanted at autopsy.hole size was 0.7 0.7 mm2, with a median hole size of 0.5
mm2 (approximately the size of a 21-gauge needle). The
total number of fabric holes per explanted device is shown
in Fig 4. Only four explanted devices (3%) had 10 or more
holes. The distribution of fabric holes per device module is
shown in Table II. Fabric holes were most often found in
the bifurcation module, with 1  2 holes per bifurcation.
There were no significant differences in the number of stent
fractures or fabric holes between preRPM fabric explants
and RPM fabric explants.
Suture integrity. Broken and abraded sutures were
found in almost all explanted devices, most commonly in
areas of severe angulation. Suture breakage was most often
seen at junction stitches between stent rings (Fig 2), and
breakage enabled partial stent ring separation or overlap.
The median number of broken sutures per explanted device
studied was 22, which was less than 1.5% of the total
number of sutures in each device.
Duration of implant. The number of fatigue frac-
tures and fabric holes as a function of implantation time is
shown in Fig 5. The number of explants at each time point
is indicated in the figure. The device with the largest
numbers of fatigue fractures (29 fractures on one extender
cuff) had been implanted for 30 months.
“For cause” versus “incidental” explantation. A
comparison of “for cause” explantation and “incidental”
explantation is shown in Table III. Patients in the world-
wide “for cause” explantation group were 6 years younger
than patients in the “incidental” explantation group (P 
.003), and their devices had been implanted 10 months
longer (P  .007). Preoperative patient risk factor analysis
in the 37 clinical trial explants revealed a higher rate of
symptomatic cardiac arrhythmia (P .02) in the “inciden-
tal” explant group, consistent with documented cardiac
cause of death in 70% of this group. Explant analysis
revealed a significantly greater number of stent fatigue
fractures and fabric holes in “for cause” explants compared
with “incidental” explants (P .005 and P .008, respec-
tively; Wilcoxon rank sum test). However, when analysis of
covariance was used to adjust for differences in duration of
implantation, the differences in fatigue fractures and fabric
holes between the two groups were not significant (P  .3
for both).
Endoleak. Among clinical trial patients endoleak was
documented on the final imaging study before explantation
in 26 patients, and was absent in 11 patients. Endoleak rate
was higher with “for cause” explants (81%) compared with
“incidental” explants (17%; P  .005). There was no
significant difference in endoleak rate between explants
with fabric holes (76%) compared with those with no fabric
holes (63%). Similarly, there was no significant difference in
endoleak rate between explants with stent fractures (78%)
compared with those with no stent fractures (57%). There
was no significant difference in the number of fabric holes
or stent strut fractures between explants from patients with
endoleak compared with those without endoleak (Table
IV).
tigue
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ical trial group, aneurysm enlargement (diameter increase
5 mm compared with baseline computed tomography
Fig 3. Number of stent strut fa
Fig 4. Number of fabric holes
Fig 5. Fractures and holes as a function of number of m
time point is indicated on the x-axis.scan) before explantation was documented in 15 patients;
22 aneurysms exhibited no enlargement. There was no
significant difference in enlargement rate between explants
fractures per explanted device.
.2 mm2) per explanted device.
s the device was implanted. Number of explants at each(0onth
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holes (44%). Similarly, there was no significant difference in
aneurysm enlargement between explants with fatigue frac-
tures (39%) compared with those with no fractures (43%).
There was no significant difference in the number of fabric
holes or strut fractures between explants from patients with
or without aneurysm enlargement (Table V).
Device migration. In the clinical trial group, pre-
explant imaging studies documented stent-graft migration
in 14 patients; 23 patients had no stent-graft migration.
Explants with stent fractures in any device module were
more likely to have migrated (52%) than were explants with
no fractures (14%; P .02). The number of stent fractures
was higher in explants from patients with stent-graft migra-
tion than in explants with no migration (P  .04; Table
VI). The number of fabric holes was higher in bifurcation
modules from patients with stent-graft migration (P 
.03); however, there was no significant difference in the
total number of fabric holes per device (P .08; Table VI).
Clinical case review. Retrospective review of clinical
records and sequential imaging studies revealed evidence of
Table II. Stent fatigue fractures and fabric holes by device
Bifurcation
n
Worldwide explanations (N  120)
One or more fatigue fractures 76 4
No. of fractures (mean  SD) 2.4  3.0 1.0
One or more fabric holes
No. of holes (mean  SD)
Clinical trial explantations (N  37)
One or more fatigue fractures 21 5
No. of fractures (mean  SD) 1.7  2.0
One or more fabric holes 16 4
No. of holes (mean  SD) 1.6  2.6
Table III. “For cause” versus “incidental” explant analysis
Worldwide explants (N 
For cause
(n  104)
No cause
(n  16)
Age at implant (y) 71  6.9 77  7.0
Gender
(%male:female)
88:12 80:20
Pre-RPM:RPM fabric
(%)
12:88 6:94
Implant duration (mo) 24  13 14  12
Any device fracture
n 74/104 5/16
% 71 31
Stent fractures per
device
3.3  4.5 1.1  2.5
Any device hole
n 51/104 3/16
% 49 19
Fabric holes per device 2.2  3.4 0.2  0.4
*Based on Wilcoxon rank sum test. When analysis of variance is used to conshort or absent device fixation length, either proximally at
the aortic neck, distally to the iliac artery, or at a modular
junction site in 86% of “for cause” explant cases. This
review suggested that inadequate device fixation was a
major cause of clinical events leading to rupture or surgical
explantation in each case. A case example, demonstrating
inadequate fixation of the modular iliac limb as the cause of
aneurysm rupture is shown in Fig 6. No structural abnor-
malities were found in the left iliac limb, whereas focal
fatigue fractures and fabric holes were found in the bifur-
cation module. Most structural abnormalities found in
explanted devices were remote from stent-graft fixation
sites, and no causal relationship between device structural
findings and clinical outcome could be established.
DISCUSSION
Despite a 7-year clinical experience, little information is
available on the structural characteristics of implanted An-
euRx devices, because clinical results are good1,6 and rela-
tively few devices have been retrieved for analysis. The
sample of 120 explanted stent grafts in this study is a small
ule
Iliac limb Extender cuff
n % n %
8 7 8 7
0.1  0.3 0.5  2.9
22 18 14 12
0.5  1.3 0.4  1.7
2 5 4 11
0.1  0.4 0.9  4.8
6 16 2 5
0.5  1.2 0.2  0.9
Clinical trial explants (N  37)
P
For cause
(n  31)
No cause
(n  6) P
.003 71  7.9 74  7.5 NS
NS 87:13 67:33 NS
NS 23:77 17:83 NS
.007 31  9 24  10 NS
.002 21/31 2/6 NS
68 33
.005* 3.2  5.3 0.5  0.8 NS (.06)*
.02 20/31 1/6 NS
65 17 (.07)
.008* 2.6  3.6 0.2  0.4 .03*
or duration of implant, P  .3.mod
%
3
 2.0
7
3120)
trol f
comp
e expla
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wide. Nonetheless, it is the largest reported systematic
structural analysis of explanted aortic devices. Although
there were some early changes in stent design (stiff to
flexible) and fabric weave (preRPM to RPM), the AneuRx
device has remained the same over the past 7 years. Thus
these explant results largely reflect the currently marketed
device. However, the sample of explants is sharply skewed
toward the minority of patients with serious adverse events,
inasmuch as 87% of worldwide explants were retrieved at
surgical explantation or after aneurysm rupture. Among the
1193 clinical trial patients, those with aneurysm rupture or
surgical conversion represented less than 4% of patients,6
but accounted for 84% of the explants in this study. Device
recovery rate in clinical trial patients who underwent surgi-
cal conversion is 80%, but device recovery is only 4% in
patients who died of non-aneurysm-related causes. Thus it
is unclear how representative these explant findings are for
the entire population of implanted devices.
Structural analysis revealed the presence of one or more
focal abnormalities in most explanted AneuRx devices,
including stent fatigue fractures, fabric holes, or suture
disruption. The structural abnormalities observed were
few, 2 or 3 stent fractures and fabric holes per device,
particularly when considered in light of the total number of
Table IV. Endoleak analysis (clinical trial patients)*
Endoleak
Fabric holes per bifurcation module 1.4 
Fabric holes per device 2.1 
Stent fractures per bifurcation module 1.9 
Stent fractures per device 3.3 
Values represent mean  SD.
*Patients with endoleak present on last imaging study prior to explantation
Table V. Enlargement analysis (clinical trial patients)*
Enlargemen
Fabric holes per bifurcation module 1.3 
Fabric holes per device 1.6 
Stent fractures per bifurcation module 1.4 
Stent fractures per device 3.8 
Values represent mean  SD.
*Patients with aneurysm enlargement (5 mm) documented on serial imag
Table VI. Migration analysis (clinical trial patients)*
Migration
Stent fractures per bifurcation module 2.5 
Stent fractures per device 4.6 
Fabric holes per bifurcation module 2.5 
Fabric holes per device 3.6 
Values represent mean  SD.
*Patients with evidence of device migration on serial imaging studies beforstructural elements in each device. Thus, for example, the
number of stent strut fractures found represented less than
0.2% of the total number of stent struts in a bifurcated
device. Nonetheless, a relatively small number of stent
fractures in critical areas of the stent graft may potentially
have an adverse effect on the structural strength of the
device. Similarly, even small fabric holes may potentially
result in type III endoleaks, pressure transmission into the
aneurysm sac, aneurysm enlargement, and possible aneu-
rysm rupture.
To assess the clinical significance of the observed stent
and fabric abnormalities we reviewed the subset of 37
clinical trial explants, because these patients, as part of the
clinical trial, had well-documented clinical follow-up with
serial imaging studies before explantation. We found no
difference in the number of fabric holes or fatigue fractures
in the explanted devices from patients with endoleaks com-
pared with those without endoleaks before explantation.
Similarly, no relationship could be established between
pre-explantation aneurysm enlargement and fabric holes or
fatigue fractures noted in explanted devices. These obser-
vations suggest that the structural findings did not account
for adverse aneurysm-related events such as endoleak and
enlargement, although the current sample size may not be
large enough to rule out this possibility. On the other hand,
26) No endoleak (n  11) P
1.9  3.1 NS
2.5  3.9 NS
1.3  1.9 NS
1.3  1.9 NS
ared with patients without endoleak.
15) No enlargement (n  22) P
1.8  2.9 NS
2.6  3.7 NS
1.9  2.1 NS
2.0  2.1 NS
udies before explanation compared with patients with no enlargement.
14) No migration (n  23) P
1.2  1.8 .04
1.6  2.2 .04
1.0  2.0 .03
1.4  2.1 .08
ntation compared with patients without migration.(n 
2.4
3.2
2.0
5.7t (n 
2.2
2.8
1.8
7.3
ing st(n 
2.0
7.3
3.2
4.6
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studies was associated with a small increase in both fatigue
fractures and fabric holes found in explanted devices. It was
not possible to determine with any degree of certainty
whether these structural findings developed before or after
the stent graft migrated.
Stent fractures found in this study were most com-
monly located in the bifurcation module, with most frac-
tures found in aortic rings 3 and 4. At this location the
round aortic stent ring configuration changes to a bi-oval
contour to accommodate the two iliac limbs. Stent struts in
this region are exposed to higher residual strain, and most
stent strut fractures in this region were individual and
uninvolved with the fixation seal zone (Fig 2). In one
instance, five strut fractures were found in aortic stent ring
3. This was the largest number of fractures found in a single
stent ring, and was associated with multiple suture breaks.
This patient had severe aortic neck angulation and eccentric
compression of the bifurcation module from an angulated
proximal aortic extender cuff. The bifurcation module sep-
arated from the aortic extender cuff after 2 years, and the
patient underwent successful open surgical repair.22 It is
believed that the angulation stress and motion between the
proximal extender cuff and bifurcation module led to sep-
Fig 6. Explant case example. A, A 24  14  16.5-cm
femoral artery to treat a 5.5-cm abdominal aortic aneurys
below the bifurcation junction gate (see markers). The
artery. The aneurysm was successfully excluded from
However, insecure fixation both proximally and distally o
of the left iliac limb and slight angulation of the bifurca
continued to be no endoleak, and no change in aneury
separation of the iliac limb from the bifurcation modu
surgical conversion. D, Explant analysis revealed fatigue
fabric holes in the angulated right iliac limb at rings 14
were no abnormalities in the left iliac limb.aration of the extender cuff.22 The second most common
site of fatigue fractures was the distal portion of iliac limbs
in areas of severe angulation and tortuousity. These frac-
tures were often outside of the aneurysm sac (Fig 6).
Fabric holes were usually related to fabric abrasion
against the apex of a stent diamond in areas of severe
angulation. These focal stent–diamond tip perforations
were small and were often located in iliac limbs, remote
from the aneurysm sac. Median hole size was 0.5 mm2,
approximately the size of a 21-gauge needle. Fabric holes
observed in explanted devices were likely to have been
plugged with thrombus or tissue in vivo, and thus it is not
surprising that there was no significant relationship be-
tween endoleak and fabric holes. It is possible that such
sealed holes may account for pressure in the aneurysm sac
without evidence of endoleak (endotension) and thus lead
to aneurysm enlargement. However, we found no relation
between fabric holes and aneurysm enlargement. Aneurysm
enlargement after endovascular repair in AneuRx clinical
trial patients, although associated with the presence of an
endoleak, is not associated with increased risk for aneurysm
rupture.23 Removal of tissue and thrombus material from
the stent-graft surface after opening the aneurysm sac dur-
ing surgical conversion may induce pinpoint bleeding
g bifurcation module was implanted through the right
14 8.5-cm-long left iliac limb was used and positioned
iac limb was too short, and barely reached the left iliac
rculation, with no evidence of endoleak (see inserts).
left iliac limb was apparent on the x-ray film. B, Bowing
odule was apparent on x-ray film at 12 months. There
ze. C, Aneurysm ruptured at 21 months as a result of
e AneuRx stent graft was explanted during successful
res in ring 3 of the bifurcation module (top arrows), and
, remote from the aneurysm sac (bottom arrows). There-lon
m. A
left il
the ci
f the
tion m
sm si
le. Th
fractu
to 16
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vices from patients with clinically reported “mic-
roleaks”24,25 revealed that they had received preRPM fabric
devices, which had weave separation but no evidence of
fabric holes. No microleaks have been reported in patients
who have received the AneuRx device made with RPM
material. Intrinsic polyester fabric failure has been noted in
aortic grafts used in open surgery,26,27 thus stimulating
continuing improvement in fabric design. It is likely that
advanced fabric designs will reduce the risk for abrasion-
induced holes in the future.
A comparison of explants removed “for cause” with
those recovered at “incidental” autopsy revealed a signifi-
cantly greater number of fatigue fractures and fabric holes
in “for cause” explants. However, there was also a signifi-
cant difference in average implant duration between the
groups, 24 months for “for cause” explants versus only 14
months for “incidental” explants. Since stent fatigue frac-
tures and fabric abrasion holes are time-dependent, analysis
of covariance was used to adjust for the difference in
duration of implantation. The differences in the number of
fatigue fractures and fabric holes between groups were not
significant when adjusted for the differences in implant
duration. Only 16 “incidental” autopsy explants were avail-
able for analysis, compared with 104 “for cause” explants.
While it is possible that increasing the number of explants in
the “incidental” group, particularly those with longer im-
plant time, would reveal significant differences between the
groups, this is not certain. Furthermore, it is likely that the
disparity between the groups will continue, given the
marked difference in device recovery rate between surgical
explants and “incidental” explants at autopsy.
Perhaps the most meaningful clinical observations
came from the review of x-ray films and serial computed
tomography scans in patients with “for cause” explants.
Image analysis revealed evidence of short stent-graft fixa-
tion length proximally, distally, or at the iliac junction in
86% of “for cause” explants. Inadequate stent-graft fixation
can be present despite complete aneurysm exclusion with
no endoleak for prolonged periods, as demonstrated by the
case shown in Fig 6. These observations are consistent with
previous reports that poor stent-graft fixation is the primary
predisposing factor for aneurysm rupture after endovascu-
lar repair with the AneuRx stent graft.10 Short proximal
fixation length is also a primary predictor of migration of
AneuRx stent grafts.28 Short proximal fixation may be the
result of low initial deployment of the device or severe
angulation of the aortic neck. Most stent, fabric, and suture
defects were remote from fixation and seal zones, and thus
did not appear to be related to the cause of explantation.
Most structural abnormalities in explants that migrated
were localized in areas of increased angulation stress, which
suggests they developed or were accentuated as a result of
stent-graft migration. However, longer follow-up and anal-
ysis of a larger number of explants will be needed to better
determine the relationship between structural findings and
migration.SUMMARY
Stent fatigue fractures, fabric holes, and suture breaks
were found in most explanted AneuRx stent grafts. These
structural findings were not significantly related to pre-
explant aneurysm enlargement or endoleak; however,
longer studies with larger sample sizes are needed to con-
firm these results. Pre-explant device migration was associ-
ated with a greater number of explant stent fractures and
fabric holes. Although “for cause” explants had a greater
number of structural abnormalities than did “incidental”
explants, these differences may be explained by differences
in duration of device implantation. Most devices explanted
“for cause” had evidence of insecure proximal, distal, or
junctional fixation, which could account for the adverse
clinical event. Thus a clear relationship to explant structural
findings could not be established. Longer studies are
needed to fully determine the significance of these explant
findings.
APPENDIX
The Medtronic Explant Program has provided impor-
tant information that has been used to enhance the AneuRx
stent-graft system. Improvements approved by the US
Food and Drug Administration in January 2004 include
use of a more densely woven graft material, high-density
graft material, which enhances the robustness of the graft
fabric.
We thank the Medtronic explant analysis team (Sus-
anne Bonnet, Jonathan Morris, Eric Johnson, Michel Le-
tort); the physicians worldwide who explanted AneuRx
endovascular devices and made them available for this
analysis; and Maria Martinez for preparation of the manu-
script.
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Available online May 6, 2004.DISCUSSION*Dr Timothy A. M. Chuter (San Francisco, Calif). I would
like to thank the committee for the opportunity to review this
interesting paper. Those of you who cannot wait to see this
information in print should read Appendix Two of the recently
published 6-year report that described 115 AneuRx explants. The
findings were essentially the same. Indeed, most of the patients
were the same. Of the 48 patients in the current study, 45 were
included in the previous report.
As Dr Zarins said, all three forms of stent-graft failure occurred
at relatively low rates when the prevalence was expressed as a
proportion of the total number of components, but that’s not the
point. A broken chain is still broken even if 99% of the links remain
intact. It is not as though there was much redundancy built into the
design of the AneuRx stent graft. Each component performed an
important and unduplicated function. The important issue here is
whether the strut breakages, suture breakages, and holes in the
graft caused migration, endoleak, endotension, or aneurysm dila-
tation or rupture. So, did broken struts cause stent-graft migration
or disruption? The answer is probably no. Most fractures occurred
in the midsection of the stent graft, not at the ends, where stent
failure would lead to failed attachment. What about suture breaks?
Did they seriously disrupt the shape of the stent graft or allow the
graft fabric to flap against the apex of the stent? The answer is yes
in some cases. The mean number of breaks was 25 to 30 per stent
graft. Most occurred at points of angulation, and some were
associated with abrasion holes. And last, but not least, the holes. It
appears weave separation rarely caused holes in the new, more
tightly woven RPM fabric, but abrasion remained a persistent
*The text of this discussion reflects what was said at the Western Vascular
Society meeting. As a result of peer review, there have since been extensive
changes to the manuscript, most notably the addition of 120 patients to
address the concern about type II statistical error and an entirely new
analysis of the data. The article is based on 48 patients plus these 120 new
patients.problem. The mean number of abrasion holes in this study was 2.2
per patient. They occurred at acute graft angulations and suture
breaks. In the 115 explant series the mean area of these abrasion
holes was 0.7 mm. Assuming the holes were roughly circular, the
mean diameter would be 0.95 mm, which would certainly be large
enough to transmit pressure, if not flow, to the aneurysm. Appar-
ently the presence or absence of holes did not correlate with the
rate of endoleak, but, as Dr Zarins has told us, many times
endoleaks are of no significance when one is talking about AneuRx
cases. I have four questions for Dr Zarins.
Number one, what was the mean diameter of the abrasion
holes in this study? Number two, how many patients exhibited
transgraft leakage at conversion? I have seen two quite striking
cases. There must be others, and perhaps they should be included
in the report. Might a prevalence of graft holes be responsible for
the relatively low rate of aneurysm shrinkage seen after endovascu-
lar repair with the AneuRx stent graft compared, for example, with
the Talent device? And finally, since stent graft angulation caused
suture breakage and abrasion holes, would Dr Zarins suggest
further narrowing the selection criteria for the AneuRx device?
Dr Christopher K. Zarins. Indeed the structural integrity is
key for long-term device performance.
With regard to the questions, the mean area was 0.7 mm2, but
the holes are small, as you saw them, in relationship to the size of
the stent. So they are small holes, approximately the size of a
21-gauge needle.
In terms of the transgraft flow, there were in fact four cases
that were related to the so-called microleak phenomenon. In this
phenomenon, in the operating room the surgeon will remove
mural thrombus from the surface of the graft, perhaps manipulate
the graft a little bit, and can produce holes with bleeding through
the graft fabric. You can actually do this with any open surgical
technique. If you have a polyester fabric sewn in place, you put a
needle in it, and that spreads the weave of the fabric, and then you
have bleeding through the needle hole, and of course you hold it
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actually what happens in these fabric weave separations, or so-
called microleaks. The cases that have been published on this
phenomenon all had the preRPM fabric, so I think that weave
separation is perhaps not really an issue with the current device.
With regard to the shrinkage rate, shrinkage or lack of shrink-
age and enlargement in these devices is primarily related to type II
endoleaks, which do persist in these devices, and the presence or
absence of a type II endoleak is related to size changes. I do not
believe they are related to these fabric abrasion holes, although I
can’t rule out that possibility.
In terms of patient selection and angulation, I think there is no
evidence to suggest that we should change our selection criteria. In
fact, these devices perform quite well in angulated areas, although
in angulations it is subject to stresses, stent fractures, abrasion
holes, and suture breaks, as we have discussed, but this does not
seem to be related to clinical outcome or clinical performance in
these areas.
Dr James Edwards (Portland, Ore). Was there any correla-
tion between the number of fractures or suture breaks and the
length of time the devices had been in place? I would expect an
increased failure rate or increased number of structural defects with
increased implant time.
Dr Zarins. There was not a statistically significant relationship
between implant duration time and the number of fatigue fractures
among clinical trial patients. That does not mean there could not
be, because the average implant time was 30 months, and the
number of devices harvested was quite small compared with the
total population of devices. So I can’t rule out the possibility that
there is a time-related relationship, but there was not in this cohort
of patients.
Dr Lloyd M. Taylor, Jr (Portland, Ore). Do you have any
information that we can use for comparison purposes on the
anticipated number of defects in the fabric of standard open
implanted polyester grafts? We have a lot of information from your
study, which is very valuable. But the question is, in routine
aneurysm repair are there defects in the fabric as well in explanted
specimens? Do you know anything about that?
Dr Zarins. Well, there is a very large body of data on graft
fabric defects in open surgical repair. There are many iterations and
evolution of graft fabrics of various types of design and weave
strength. You may recall the old Wesolowski graft, which was an
ultra-lightweight fabric that ultimately broke down. The fabric
degenerated and caused aneurysmal dilatation of the graft fabric.
So I think the graft fabric is a very important issue, both open
surgical and endograft designs, and it is, in fact, what really holds
everything together. The fabric itself is a very, very critical compo-
nent in both open and endografts. On the basis of the findings
from this explant program, I believe the manufacturer is planning
on increasing, yet again, the strength and durability of the fabric
that is used in this particular device.
Dr Sam Ahn (Los Angeles, Calif). I still have a hard time
accepting your conclusion that there is no causal relationship
between the structural defects and the clinical outcome. I just
wonder if that lack of conclusion of that relationship could be due
to a type II statistical error, since this is a relatively small series. You
are looking at a very select group of patients, those that underwent
graft explantation. There may be a lot of other structural defects inother patients that aren’t causing problems and we just haven’t
discovered them yet. I was wondering if you could comment on
the possibility that this could be a sampling error or a type II
statistical error. Also, a second point is that, as I have listened to a
lot of talks, including yours, about device failures, every time they
present some example of a failure it seems like, in retrospect, if we
had not “pushed the envelope” in that particular patient that
failure might not have happened. I wonder if the message from
your paper is that we should not “push the envelope” so much, and
maybe we shouldn’t treat so many patients with really adverse
anatomic factors.
Dr Zarins. I cannot exclude the possibility of a statistical error
since we had only 48 devices from 1193 patients. Error can also be
made on the basis of generalization from anecdotal cases. For
example, a study of 25 explanted devices, or 25 failures, found
angulation of the neck, leading some to say, “Ah, that means we
should not do angulated cases.” Well, the error there is that you
never looked at the successes. In our own experience we have a lot
more successes with angulations than we have failures, long-term
successes that work very, very well. So you can’t necessarily con-
clude that, because you have a couple of failures, everyone who has
that feature, like an angulation, is going to fail. It’s not actually true
(see footnote on previous page).
Dr William Quinones (Los Angeles, Calif). It is precisely
because of that that I raise one question, and that is, are you
looking at the patients who are still “successes” to see if there is any
evidence of any of these types of failures with perhaps an increased
or more intense follow-up program and imaging? That’s my first
question.
In relationship to the first question, the reason I think that is
important is because it will answer the question. If you know that
there are specific defects in a patient that are still in place and
nothing happens, then it supports your conclusion, but if we start
seeing some of these defects prior to a failure of the implant, then
I think you may need to modify your conclusion.
My second question is, have you shared this information with
the FDA, and if you have, what has been their recommendation in
terms of follow-up for the patients who still have the implant?
Dr Zarins. Yes, this has been shared with the FDA, and the
outcome of that recommendation of the FDA is, in fact, what you
suggested in the first part of your question, that is, closer follow-up
of anyone who has been identified to have anything that has been
suggested as being an adverse issue, for example, the stiff device.
We know that the risk for rupture with a stiff device is higher than
with the segmented flexible device. However, that was a very early
issue related to the stiffness, pulling out in areas of angulation. The
response was to follow these patients at 3-month or 6-month
intervals instead of yearly intervals. In fact, nothing has happened
to these patients. It was an early issue. So a regulatory response to
demand follow-up or early imaging may or may not be that
productive. Our own practice is to follow up patients on the basis
of clinical parameters and clinical outcome measures, and in fact
the clinical outcome measures are quite good. I think the ultimate
answers will come out in the long-term follow-up, because the
follow-up is going to be forever in this cohort of patients, and we
hope we will collect as large a number of explants, either autopsy or
surgical explant, and be able to further answer some of these
questions.
